CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 15 filers reported holding CLOVIS ONCOLOGY INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $667,000 | -20.6% | 560,565 | +20.1% | 0.00% | – |
| Q2 2022 | $840,000 | -10.8% | 466,652 | 0.0% | 0.00% | – |
| Q1 2022 | $942,000 | -19.9% | 466,652 | +7.5% | 0.00% | – |
| Q4 2021 | $1,176,000 | +278.1% | 433,983 | +1355.7% | 0.00% | – |
| Q4 2019 | $311,000 | +63.7% | 29,812 | -38.5% | 0.00% | – |
| Q3 2019 | $190,000 | -80.1% | 48,482 | -24.5% | 0.00% | – |
| Q2 2019 | $955,000 | +112.7% | 64,218 | +254.9% | 0.00% | – |
| Q1 2019 | $449,000 | -16.1% | 18,095 | -0.7% | 0.00% | – |
| Q3 2018 | $535,000 | -66.1% | 18,215 | -39.1% | 0.00% | – |
| Q1 2018 | $1,579,000 | +241.8% | 29,911 | +9103.4% | 0.00% | – |
| Q4 2017 | $462,000 | -99.5% | 325 | -100.0% | 0.00% | -100.0% |
| Q1 2017 | $84,788,000 | +14594.6% | 1,331,669 | +10143.6% | 0.02% | – |
| Q4 2016 | $577,000 | -91.6% | 13,000 | -93.2% | 0.00% | -100.0% |
| Q3 2016 | $6,890,000 | – | 191,122 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
| Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
| NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
| EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
| Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
| Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
| PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
| Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
| Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |